Novartis $2 million gene therapy for rare disorder is world's most expensive drug

Novartis $2 million gene therapy for rare disorder is world's most expensive drug Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.The Food and Drug Administration approved Zolgensma for children...

Read More